CD274 and neoplasm: After 4 weeks of the combined treatment, a significant survival improvement and a decline in the proportion of mice with tumours were observed in this model, indicating the potential of the anti-PD-L1/anti-VEGF dual treatment in overcoming resistance to either of a single agent.